Key result
Known malignancy is linked to ~4.4-fold higher odds of neoplastic pericardial involvement.
Why the study?
Pericardial effusion may be the first manifestation of an occult malignancy, but the diagnostic contribution of pericardial fluid cytology according to oncological status was unclear.
Does pericardial fluid cytology and pathological assessment help identify occult malignancy and distinguish malignant from non-neoplastic pericardial involvement?
Observational (n=209)
No
Does pericardial fluid cytology and pathological assessment help identify occult malignancy and distinguish malignant from non-neoplastic pericardial involvement?
Pericardial fluid cytology provides critical diagnostic utility by revealing occult malignancies in patients presenting with large effusions, and by distinguishing malignant from non-neoplastic pericardial involvement in patients with known cancer.
Answers are grounded in this paper and cite their sources.
Cytology in pericardial effusions may identify occult malignancy; leaves open whether routine testing improves outcomes in patients without known cancer.
Background/Objectives: Pericardial effusion may occur in patients with established cancer but may also represent the first manifestation of an occult malignancy. This study evaluated the diagnostic contribution of pericardial fluid cytology and pathological assessment according to previous oncological status, with particular emphasis on previously unrecognized malignancy. Methods: We conducted a retrospective observational study of patients hospitalized with pericardial disease between January 2021 and December 2025 at a tertiary cardiovascular center. The final cohort comprised 234 clinical episodes in 209 patients. Clinical, laboratory, imaging, procedural, cytological, and histopathological data were analyzed in relation to previous oncological status and malignant pericardial involvement. Results: Pathological assessment was available in 95/234 episodes (40.6%), with neoplastic involvement identified in 21/95 (22.1%). Neoplastic findings occurred in 13/33 (39.4%) evaluable episodes with known malignancy and 8/62 (12.9%) without a previous cancer diagnosis (odds ratio, 4.39; 95% confidence interval, 1.59–12.11; p = 0.004). Conversely, 20/33 (60.6%) evaluable episodes in patients with known cancer showed no neoplastic involvement. In all eight patients without previously known malignancy, pericardial fluid cytology provided the first pathological evidence of cancer; six (75%) had findings suggestive of a pulmonary origin. All presented with large effusions and hemodynamic compromise. Conclusions: Pericardial pathological assessment provides diagnostic information beyond previous oncological status. It can distinguish malignant from non-neoplastic pericardial involvement in patients with established cancer while also revealing occult malignancy when pericardial disease is its first presentation.
No takes yet. Share an insight, caveat, or question.
Munteanu et al. (2026) conducted an observational in Pericardial disease (n=209). Known malignancy vs. No previous cancer diagnosis was evaluated on Neoplastic pericardial involvement on pathological assessment (OR 4.39, 95% CI 1.59-12.11, p=0.004). Known malignancy was associated with higher neoplastic pericardial involvement compared to no prior cancer diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: